sorafenib has been researched along with tamibarotene in 1 studies
| Studies (sorafenib) | Trials (sorafenib) | Recent Studies (post-2010) (sorafenib) | Studies (tamibarotene) | Trials (tamibarotene) | Recent Studies (post-2010) (tamibarotene) |
|---|---|---|---|---|---|
| 6,520 | 730 | 5,251 | 198 | 10 | 105 |
| Protein | Taxonomy | sorafenib (IC50) | tamibarotene (IC50) |
|---|---|---|---|
| Chain A, PROTEIN (CRABP-I) | Bos taurus (cattle) | 0.14 | |
| Chain A, PROTEIN (CRABP-II) | Homo sapiens (human) | 0.14 | |
| Chain A, PROTEIN (CRABP-II) | Homo sapiens (human) | 0.14 | |
| Retinoic acid receptor alpha | Homo sapiens (human) | 0.078 |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 1 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Ishijima, N; Kanki, K; Shimizu, H; Shiota, G | 1 |
1 other study(ies) available for sorafenib and tamibarotene
| Article | Year |
|---|---|
Activation of AMP-activated protein kinase by retinoic acid sensitizes hepatocellular carcinoma cells to apoptosis induced by sorafenib.
Topics: Adenosine Triphosphate; AMP-Activated Protein Kinases; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; bcl-2-Associated X Protein; Benzoates; Carcinoma, Hepatocellular; Cell Line, Tumor; Gene Expression Regulation, Neoplastic; Glucose Transporter Type 1; Humans; Liver Neoplasms; Niacinamide; Phenylurea Compounds; Retinoids; Sorafenib; Tetrahydronaphthalenes; Tretinoin | 2015 |